Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.
Mascarella MA, Olonisakin TF, Rumde P, Vendra V, Nance MA, Kim S, Kubik MW, Sridharan SS, Ferris RL, Fenton MJ, Clayburgh DR, Ohr JP, Joyce SC, Sen M, Herman JG, Grandis JR, Zandberg DP, Duvvuri U.
Mascarella MA, et al.
Clin Cancer Res. 2023 Feb 16;29(4):723-730. doi: 10.1158/1078-0432.CCR-22-1768.
Clin Cancer Res. 2023.
PMID: 36595540
Free PMC article.